Morgan Stanley upgrades Nucor rating and lifts price target to $310

Morgan Stanley raised its rating on Nucor to Overweight (later reported as Outperform) and increased its price target from $300 to $310. The upgrade was driven by the company's capital‑spending outlook, strong cash‑flow generation and expected free‑cash‑flow inflection as capex declines. The new target implies about 22.7% upside from the prior close of $252.67.

The higher rating and price target suggest investors may view Nucor as more attractive, potentially supporting the stock price. Morgan Stanley expects lower capital expenditures to boost free cash flow and give the company more flexibility for shareholder returns.

  • 1Morgan Stanley upgraded Nucor to Overweight from Equal‑Weight and raised its price target to $310 from $300.
  • 2Morgan Stanley later described the rating as Outperform and cited a strong cash‑flow outlook.
  • 3The $310 target implies a 22.7% upside from the November 16 close of $252.67.
  • 4Morgan Stanley forecasts capital expenditures falling to about $1.5 billion annually in 2027‑2028, down from $2.5 billion in 2026.
  • 5The firm expects a free‑cash‑flow yield of roughly 11% over the next two years.

Sources